-
Mashup Score: 101DR. LEWIS: Interviewing my doctor by Live Today - 1 day(s) ago
In this episode of The Live Today podcast we interview Dr. Lewis, Brinlee’s oncologist, who shares his incredible journey from losing his father to cancer at age 8 to becoming an oncologist himself. During his medical training, Dr. Lewis self-diagnosed his own cancer, a challenge that shaped his outlook on life and care. Hear his inspiring story, perspectives on living fully, and wisdom on overcoming adversity.
Source: creators.spotify.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 103Products - 1 day(s) ago
Products that are inspired by a perspective change that came from a cancer diagnosis. Join our community of hope.
Source: theportstudio.comCategories: General Medicine News, Hem/OncsTweet-
In Brinlee's case, not only is she now in good health, but she is alchemizing her own difficult disease course to improve the experience of other patients with cancer, creating a line of clothing allowing for easier IV access while undergoing treatment https://t.co/KVkgfOaDqz
-
-
Mashup Score: 14
Two U.S. companies teamed up to treat cancer patients using an unproven blood filter in Antigua, out of reach of American regulators.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet-
A cautionary tale of overpromising & under-delivering to understandably desperate patients with cancer As an oncologist I am constantly trying to distinguish legitimate hope from hype and, when it sounds too good to be true, scrutinizing the data https://t.co/4nclobzMSe
-
-
Mashup Score: 10
In the article that accompanies this editorial, Lorenzen et al 1 report exploratory efficacy findings, focused on pathologic response, of neoadjuvant immunotherapy–containing chemotherapy in patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma (GEA) in the ongoing DANTE/FLOT8 trial. DANTE is an open-label phase II/III trial (German AIO) in which patients are randomly assigned to receive pre-/post-operative FLOT with atezolizumab versus FLOT alone. To our knowledge, the current
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Per Harry Yoon @MayoCancerCare pathologic response is NOT a valid surrogate for overall survival in gastroesophageal cancer, but how *do* they correlate? https://t.co/DdPTLOQA1H #GI25 https://t.co/i37bp0Kkm3
-
-
Mashup Score: 14
Two U.S. companies teamed up to treat cancer patients using an unproven blood filter in Antigua, out of reach of American regulators.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet-
A cautionary tale of overpromising & under-delivering to understandably desperate patients with cancer As an oncologist I am constantly trying to distinguish legitimate hope from hype and, when it sounds too good to be true, scrutinizing the data https://t.co/4nclobzMSe
-
-
Mashup Score: 1It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma - 3 day(s) ago
We read the CALGB (Cancer and Leukemia Group B) 80403 study results with interest. 1 This randomized three-arm trial added cetuximab to each of three chemotherapy regimens: ECF (epirubicin, cisplatin, and fluorouracil [FU]), IC (irinotecan plus cisplatin), and FOLFOX (oxaliplatin, leucovorin [LV], and FU). The intention of this trial design was to establish a biochemotherapy regimen that might be suitable as an experimental arm in a future phase III trial. However, none should be considered for further
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
https://t.co/RzdNvobwAu
-
-
Mashup Score: 2Granzyme B PET/CT Imaging Evaluates Early Response to Immunotherapy in Gastric Cancer - PubMed - 3 day(s) ago
In several malignancies, only a limited number of patients respond to immune checkpoint inhibitors. Predicting and monitoring responses to these inhibitors represent an unmet clinical need. Here, we developed a PET/CT probe targeting granzyme B, [68Ga]Ga-NOTA-Gly-Gly-Gly-Ile-Glu-Pro-Asp-C …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
Primary source: https://t.co/jJLmxF1Q3Z
-
-
Mashup Score: 14
Two U.S. companies teamed up to treat cancer patients using an unproven blood filter in Antigua, out of reach of American regulators.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet-
A cautionary tale of overpromising & under-delivering to understandably desperate patients with cancer As an oncologist I am constantly trying to distinguish legitimate hope from hype and, when it sounds too good to be true, scrutinizing the data https://t.co/4nclobzMSe
-
-
Mashup Score: 20Inhibition of Chemokine Receptor Expression on Uveal Melanomas by CXCR4 siRNA and Its Effect on Uveal Melanoma Liver Metastases - 23 day(s) ago
To determine whether blocking the expression of the chemokine receptor CXCR4 using siRNA inhibits chemotactic responses of human uveal melanoma cells to liver-derived factors and prevents liver metastases. Human uveal melanoma cells were transfected …
Source: pmc.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
@AaronGoodman33 It seems to be chemotaxis through CXCR4 : ( https://t.co/dMRH7eqzNI
-
-
Mashup Score: 182BYU names Mark Ott as inaugural dean of BYU Medical School - 27 day(s) ago
With approval from its Board of Trustees, Brigham Young University has appointed Dr. Mark Ott as the inaugural dean of BYU’s medical school.
Source: news.byu.eduCategories: General Medicine News, Hem/OncsTweet-
In my medical career I have never known a servant leader quite like Dr. Mark Ott A skilled surgeon who saved countless lives (including my own!) he now takes his considerable talents to BYU where he will be the founding dean of their medical school https://t.co/y3NTcBstVD https://t.co/bH5Cl4rexW
-
I was honored to speak to her and her sister Mariela about all of this on their Live Today podcast, as I think storytelling is an incredibly powerful vehicle for change Yes, our studies are girded by statistical power but each patient is their own n=1 https://t.co/KaLVMGUuVu